Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Astech Projects Comes of Age at 18 Years Old

Published: Wednesday, July 10, 2013
Last Updated: Wednesday, July 10, 2013
Bookmark and Share
Astech celebrates milestone by offering free consultations and proposal of their turnkey approach to automation.

Astech was started with the founders’ vision to be “recognised as one of the world’s best” in the design and supply of custom robotics and automation for use in advanced manufacturing industries including pharmaceutical, medical device, consumer healthcare, petro-chemical and chemical. This has largely been achieved by providing the very best automation solutions tailored to customer’s unique and individual requirements.

Having gone from strength to strength with an increasing sized workforce, two relocations to larger premises and a Queen’s Award for Enterprise: Innovation, Astech Director, Anthony Moran commented “This is a significant milestone for us and we hope it reinforces our reputation for quality and longevity. We have ambitious plans to broaden our product portfolio and to keep offering valuable solutions to our customers”. He continued: "We are committed to being ‘best in class’ and if we continue to improve we can only become even more successful.  In addition to thanking our dedicated Astech team for all their hard work and commitment over the last 18 years we would like to thank our many clients that have entrusted Astech to provide them with innovative and intelligent design solutions”
 
To celebrate their anniversary Astech are currently offering a free consultation and proposal of their novel turnkey approach to automation which can consist of four key steps: (1) consultation & proposal, (2) concept design study, (3) proof of concept(s) and (4) detailed design, manufacture and testing. Simply complete the online form and one of Astech’s specialist Business Development Mangers will contact you.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Immunotherapy Reduces Rheumatoid-Linked Cardiovascular Risk
Study shows combination of two extra-low dose anticytokines reduces disease activity and cardiovascular events.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!